Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Tranylcypromine

Plain-language summaryIntrigue 65 / 100

Tranylcypromine (Parnate) is a first-generation MAOI from 1961 with a chemical backbone closely related to amphetamine. That structural quirk gives it a small but real direct stimulant component on top of the MAO inhibition, producing faster onset (1 to 2 weeks rather than the 4 to 6 weeks typical of MAOIs) and a more activating subjective profile than phenelzine. It carries the same dietary tyramine restrictions and drug interaction risks as the rest of its class. Like phenelzine it earns its place in the modern psychiatric armamentarium specifically for treatment-resistant depression cases where everything else has failed. The recent Tranylcypromine in Treatment-Resistant Depression literature has revived interest in disciplined modern use of these older drugs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Decades-old irreversible MAOI with real clinical history but negligible frontier research appeal

Look, tranylcypromine is a compound researchers already know. FDA-approved in 1961 under Parnate, it was the first non-hydrazine MAOI and carries a structurally unusual cyclopropylamine scaffold that bears a family resemblance to amphetamine. That amphetamine relationship is actually what makes it marginally more interesting than phenelzine on paper: in addition to irreversible MAO-A and MAO-B inhibition, it produces weak monoamine release, which probably explains the faster clinical onset (1 to 2 weeks versus 3 to 6 for phenelzine) and the mildly activating subjective profile investigators and clinicians have described for decades.

The mechanism, though, isnt novel. Irreversible non-selective MAO inhibition is 60-year-old pharmacology. The tyramine cheese effect is a textbook drug interaction. Plasma half-life is short (1.5 to 3.2 hours) but enzyme recovery is slow (5 to 10 days), which creates the dietary and drug-interaction burden that has made this class clinically awkward and commercially marginal since SSRIs came along. For a bench scientist, that interaction profile isnt interesting, its inconvenient background noise.

Where it retains real, if modest, value is as a reference compound. If your program is probing MAO biology, monoamine release, or you need a positive control in a dopaminergic assay, tranylcypromine is a well-characterized tool with known selectivity and a deep pharmacokinetic record. The (-)-trans isomer is the pharmacologically dominant form; the clinical preparation is racemic, which opens a stereochemistry question that’s occasionally been worth pursuing. And the cyclopropylamine scaffold itself has inspired structural analogs in newer programs, so investigators doing scaffold-level work sometimes keep it on the bench as a structural reference.

We dont think it belongs at the center of a serious research program right now. Treatment-resistant depression is genuinely interesting territory, and MAOIs are experiencing mild clinical rehabilitation in TRD discussions, but that reappraisal largely benefits phenelzine data and the class generally rather than generating new mechanistic questions specific to tranylcypromine. The frontier in TRD has moved toward ketamine, psychoplastogens, and the early GLP-1/neuroinflammation angle. If youre studying MAO biology specifically, selegiline gives you selective MAO-B inhibition for a cleaner dissection. If youre studying irreversible MAO-A, phenelzine has deeper clinical literature.

Tranylcypromine is a mature, approved drug with decades of human data. That means the evidence quality is better than most compounds in this library, and the translational signal is real. But research-merit scoring isnt about knowing a compound works. It’s about whether theres something left to discover. Here, the well is mostly dry.

Novelty

18

Mechanism promise

32

In-category differentiation

38

Evidence quality

60

Translational signal

58

Research bench value

55

Rationale Tranylcypromine scores low on novelty and mechanism because non-selective irreversible MAO inhibition is thoroughly mapped 1960s pharmacology, and the amphetamine-like dual mechanism is a curiosity rather than a research catalyst. Its bench value as a non-hydrazine MAOI reference compound and positive control in monoamine release assays keeps the overall from falling below the low forties, but theres no active frontier here.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Irreversible non-selective MAO inhibitor (amphetamine-related)

A non-hydrazine cyclopropylamine MAOI structurally related to amphetamine; rapid-onset compared to phenelzine.

Abstract

Tranylcypromine ((1S,2R)-2-phenylcyclopropan-1-amine; CAS 155-09-9; molecular formula C9H11N; molecular weight 133.19) is a non-hydrazine cyclopropylamine MAOI approved by the FDA in 1961 under the trade name Parnate. The cyclopropylamine scaffold is structurally related to amphetamine, producing weak monoamine release in addition to MAO inhibition; the result is faster antidepressant onset (1 to 2 weeks) than phenelzine (3 to 6 weeks) and a mildly activating subjective profile. Inhibition of both MAO-A and MAO-B is irreversible, with similar tyramine cheese-effect risk. Plasma half-life is 1.5 to 3.2 hours, but enzyme inhibition persists for 5 to 10 days. The (-)-trans isomer is the predominant active form; clinical preparations are racemic. Hepatic metabolism is minor; the compound is largely excreted unchanged. Approved for major depressive disorder; used in atypical and treatment-resistant depression. Used as a non-hydrazine MAOI reference compound and as a positive control in dopaminergic and norepinephrine release studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-227Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Phenelzine

Plain-language summaryIntrigue 64 / 100

Phenelzine (Nardil) is a first-generation, non-selective MAOI from 1961 that irreversibly destroys both forms of monoamine oxidase, the enzymes that break down serotonin, norepinephrine, and dopamine. The result is a powerful boost in all three neurotransmitters but with the famous catch: any food containing tyramine (aged cheese, cured meats, fermented soy, certain wines) can trigger a hypertensive crisis severe enough to cause stroke, because the gut enzymes that normally clear dietary tyramine are gone. Many drug interactions are similarly dangerous. Despite all this, phenelzine remains genuinely useful for atypical depression and treatment-resistant depression where SSRIs and SNRIs have failed, because the broad monoamine boost can succeed where narrower drugs have not. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

35/100

A first-generation MAOI whose research moment passed decades ago; niche clinical value, minimal frontier interest

Look, phenelzine is sixty-plus years old. FDA cleared in 1961, it’s one of the original hydrazine MAOIs, and the research community has had decades to pick it apart. The mechanism is well understood, the liabilities are well documented, and the clinical niche it occupies, atypical and treatment-resistant depression, has been carved out since the 1970s. That doesnt make it useless, but it does make it exactly the kind of compound that scores low on a research-merit rubric built to surface things worth investigating right now.

The mechanism is genuinely interesting pharmacologically, just not novel. Phenelzine covalently inactivates both MAO-A and MAO-B by forming a hydrazine adduct at the FAD prosthetic group. Because the inhibition is irreversible, the effective duration of enzyme suppression is 14 to 21 days, fully decoupled from the plasma half-life of 11.6 hours. This produces sustained, non-selective monoamine elevation across serotonin, norepinephrine, and dopamine pathways simultaneously. There’s also a secondary angle that doesn’t get nearly enough attention: phenelzine’s hydrazine metabolites inhibit GABA transaminase, raising GABAergic tone and likely contributing to its efficacy in PTSD and anxious depression. We think that angle is legitimately underexplored. But calling it a novel mechanism in 2025 would be a stretch.

The tyramine problem is the defining liability. Dietary tyramine, normally cleared by intestinal MAO-A, accumulates under full MAO blockade and triggers norepinephrine release from sympathetic terminals, producing hypertensive crisis. The dietary restrictions are real and onerous. Modern selective reversible inhibitors like moclobemide avoid most of this, and that makes phenelzine a harder sell as a primary research focus. For basic MAO biology, cleaner tools exist: clorgyline (selective MAO-A) and low-dose selegiline (selective MAO-B) give mechanistically tighter answers without the tyramine confound.

The evidence base is real, if dated. Multiple controlled trials from the 1960s through the 1980s established efficacy in atypical depression, and the Quitkin group’s classification of atypical features, mood reactivity, hypersomnia, leaden paralysis, rejection sensitivity, was built partly around phenelzine response profiles. VA collaborative work extended phenelzine’s profile into PTSD. The clinical signal is not in doubt. The methodology is just pre-modern by current RCT standards.

We don’t see phenelzine as a compelling research target for most programs right now. It retains a specific clinical role for patients who’ve failed SSRIs, SNRIs, and TCAs, and it’s a genuine landmark in the history of biological psychiatry. But as a probe, cleaner selective tools exist. As a novel indication target, the low-hanging fruit has been picked. Honest score: this is a 1960s compound with a narrow remaining niche, not something sitting at the frontier of anything active.

Novelty

12

Mechanism promise

22

In-category differentiation

28

Evidence quality

58

Translational signal

68

Research bench value

35

Rationale Phenelzine is a 1961-approved hydrazine MAOI with fully characterized mechanism and mature evidence base; novelty and differentiation are both very low, held up only by evidence and translational scores reflecting genuine historical clinical work. No structural cap binds, but the raw calculation lands near 35 regardless.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Irreversible non-selective MAO inhibitor (hydrazine)

A first-generation hydrazine MAOI; a non-selective irreversible inhibitor still used for atypical and treatment-resistant depression.

Abstract

Phenelzine (2-phenylethylhydrazine; CAS 51-71-8; molecular formula C8H12N2; molecular weight 136.19) is a hydrazine class non-selective irreversible monoamine oxidase inhibitor approved by the FDA in 1961 under the trade name Nardil. The compound covalently inactivates both MAO-A and MAO-B by hydrazine-mediated cofactor adduction at the FAD prosthetic group; recovery requires de novo enzyme synthesis (approximately 14 to 21 days). The non-selective inhibition increases brain serotonin, norepinephrine, and dopamine concurrently, producing classical MAOI antidepressant pharmacology along with the well-known tyramine cheese-effect risk: dietary tyramine, normally degraded by intestinal MAO-A, accumulates and triggers hypertensive crisis through indirect sympathomimetic action. Plasma half-life is 11.6 hours, but the irreversible binding produces effective enzyme inhibition for 2 to 3 weeks. Hydrazine metabolism may produce hepatotoxic byproducts; chronic dosing requires hepatic monitoring. Approved for major depressive disorder; remains a benchmark for atypical depression with reverse vegetative features and for treatment-resistant cases where SSRIs and TCAs have failed.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-226Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Rasagiline

Plain-language summaryIntrigue 66 / 100

Rasagiline (Azilect) is a second-generation MAO-B inhibitor from Teva, approved by the FDA in 2006 for Parkinson disease. It is structurally distinct from selegiline (built around an indane scaffold rather than a phenethylamine) and the key practical advantage is that the body does not break it down into amphetamine derivatives. That eliminates one of the more annoying features of selegiline and makes drug screening cleaner. Like selegiline it binds MAO-B irreversibly, so a single daily dose keeps the enzyme suppressed for weeks. The ADAGIO trial controversially suggested it might also slow disease progression rather than just treat symptoms, although that finding has not been universally accepted. Used as monotherapy in early Parkinson and as an add-on in advanced disease. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

47/100

Mature MAO-B reference standard with solid clinical evidence but limited frontier research appeal

Rasagiline is the second-generation irreversible MAO-B inhibitor that largely displaced selegiline’s role in Parkinson pharmacology by doing one thing better: it doesn’t metabolize to amphetamines. That’s a meaningful difference in practice. No methamphetamine or l-amphetamine metabolites means cleaner drug-screen profiles, no cardiovascular overstimulation at clinical doses, and no tyramine restriction at the approved 1 mg daily dose. Teva’s development team got this right, and the FDA agreed in 2006. The PRESTO, TEMPO, and LARGO trials gave it solid regulatory legs across both monotherapy and levodopa-adjunct settings.

The more interesting research angle isnt the MAO-B inhibition itself, which is textbook at this point, but the propargylamine-mediated neuroprotection signal that sits underneath it. The propargyl group appears to influence Bcl-2 family expression, APP processing, and mitochondrial membrane stability through mechanisms that are partly independent of MAO-B. The ADAGIO delayed-start trial tried to pin this down. At 1 mg, it showed a weak disease-modification signal; at 2 mg, it didn’t, which muddied the interpretation. The FDA reviewed this carefully and declined a neuroprotection label claim, but the biological question isnt fully closed, and several groups have continued probing propargylamine biology in cell and rodent models. Thats where the remaining bench interest lives.

Here’s the thing though: rasagiline isnt on the frontier anymore. Safinamide arrived as a reversible, selective MAO-B inhibitor with an additional sodium-channel and glutamate-release angle that gives it a more interesting pharmacological story for combination PD research. The longevity-oriented MAO-B work has largely migrated toward broader monoamine biology in the context of aging rather than Parkinson’s specifically, and rasagiline doesn’t have the novel positioning to anchor that conversation the way a mitochondrial-targeted peptide or an mTOR-adjacent compound might. Its 14:1 MAO-B selectivity is good; it’s just not surprising anymore.

We think rasagiline earns its place in a research library as a reference standard rather than a frontier target. If your program involves dopamine metabolism, MAO-B selectivity profiling, or the propargylamine neuroprotection hypothesis, it’s a clean, well-sourced, thoroughly characterized tool. The irreversible kinetics are well-documented; the approximately 14-day recovery period is practically useful for experimental design. It’s just not a compound where bench work is likely to surface surprising findings in 2026. The primary questions have been asked, the big trials are done, and the remaining uncertainty around neuroprotection is real but not easily resolved at bench scale. Solid compound. Not an exciting one.

Novelty

22

Mechanism promise

38

In-category differentiation

42

Evidence quality

72

Translational signal

68

Research bench value

52

Rationale Rasagiline scores well on evidence and translational signal as an FDA-approved Phase 3-validated drug, but nearly 20 years of market presence and a fully characterized mechanism drag novelty and differentiation down sharply; safinamide’s reversible inhibition plus glutamate-modulation angle has moved the field forward, leaving rasagiline as a clean reference compound rather than a compelling new research target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective irreversible MAO-B inhibitor (second-generation)

A second-generation propargyl MAO-B inhibitor lacking the amphetamine metabolites of selegiline.

Abstract

Rasagiline ((R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; CAS 136236-51-6; molecular formula C12H13N; molecular weight 171.24) is a second-generation irreversible MAO-B inhibitor developed at Teva and approved by the FDA in 2006 under the trade name Azilect. Structurally distinct from selegiline by the indane scaffold replacing the phenethylamine, rasagiline does not yield amphetamine-class metabolites, simplifying its drug screening profile and avoiding the subjective stimulation associated with selegiline. MAO-B selectivity is approximately 14:1 over MAO-A at clinical dose (1 mg daily); the inhibition is irreversible and recovery requires de novo enzyme synthesis (approximately 14-day washout). Approved as monotherapy in early Parkinson disease and as adjunct to levodopa in advanced disease. The ADAGIO trial suggested possible disease-modifying effect for the 1 mg dose, though this remains debated. Tyramine restriction is not required at 1 mg daily; at higher experimental doses (2 mg) the cheese-effect risk emerges. Plasma half-life is approximately 3 hours, but the irreversible binding produces effective enzyme inhibition for weeks. Used as a reference second-generation MAO-B inhibitor in Parkinson research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-225Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Trimipramine

Plain-language summaryIntrigue 50 / 100

Trimipramine (Surmontil) is the odd duck of the tricyclic family. A single methyl group on the side chain disrupts its ability to block the serotonin and norepinephrine pumps, so it does almost none of the standard tricyclic action. Instead its effects come from heavy histamine receptor blockade plus blocking a basket of serotonin, alpha-1, and dopamine receptors. The result is a strongly sedating drug used mainly for depression with prominent insomnia. It is one of the few antidepressants that does not suppress REM sleep. Approved by the FDA in 1979, it remains in use mostly in Europe. The mechanism is interesting precisely because it shows that an antidepressant does not necessarily need monoamine reuptake inhibition to work. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

Unusual non-transporter TCA with narrow but genuine probe value for mechanism dissection

Look, trimipramine is genuinely unusual among TCAs, and thats actually the only reason it earns a spot in a serious research library at all. Most tricyclics work by hammering SERT and NET: imipramine, amitriptyline, nortriptyline, all of them. Trimipramine does something different. SERT Ki sits around 150 nM and NET Ki is an almost useless 2400 nM, which means the monoamine transporter story basically drops out. What’s left is extremely potent H1 antagonism (Ki ~0.27 nM, comparable to first-generation antihistamines), strong 5-HT2A and alpha-1 blockade, and meaningful D2 antagonism. That pharmacological profile makes it an interesting tool for one specific job: dissecting what TCAs actually do when you remove the transporter component.

We think the bench utility here is real but narrow. If you’re investigating whether TCA antidepressant effects are truly transporter-dependent, or you want to understand the separate contributions of H1 and D2 blockade to sedation, sleep architecture, or antipsychotic-adjacent activity, trimipramine is a legitimate reference point. Riemann et al. in the early 1990s showed it preserved slow-wave sleep without the REM suppression typical of SERT-active TCAs, which is genuinely interesting and hasn’t been replicated often enough. That’s the kind of signal worth chasing if sleep architecture is your question.

What we don’t like: this is a 1979 FDA approval with a mechanism that’s been understood for decades. The H1 story isn’t new. D2 antagonism isn’t new. The weak-transporter TCA angle is a curiosity more than a frontier. There’s no recent surge of interest, no emerging indication that elevates it, and the clinical literature is thin compared to amitriptyline or nortriptyline. The depression and insomnia data mostly predates modern trial standards, and we’re not aware of serious ongoing programs studying it in genuinely novel contexts.

The differentiation story is honestly pretty weak outside that specific probe application. For sedation research you’d compare against doxepin (similarly potent H1, more evidence in primary insomnia), quetiapine (D2 and H1 profile backed by a much larger evidence base), or mirtazapine (cleaner H1 with better tolerability data across modern trials). Trimipramine doesn’t dominate any of those comparisons except in the non-transporter TCA niche. The pharmacokinetics are also messy: half-life spans 16 to 40 hours and CYP2D6, CYP2C19, and CYP3A4 all participate, which complicates clean interpretation in multi-compound bench work.

Honestly, if your research question is specifically what TCA pharmacology looks like without the transporter contribution, trimipramine is your molecule. That’s a real question with real mechanistic weight. But if you’re casting wider, there are better targets at almost every other point in this space. The score reflects both the genuine probe utility and the limited scope of that utility.

Novelty

20

Mechanism promise

40

In-category differentiation

42

Evidence quality

60

Translational signal

58

Research bench value

55

Rationale Trimipramine’s methyl substitution almost abolishes SERT and NET activity, leaving an unusually pure H1/D2/5-HT2A antagonism profile that gives it real but narrow utility as a reference probe for dissecting non-transporter TCA effects. Low novelty as a 1979 approval with fully understood pharmacology anchors the score; bench value for specific mechanistic questions provides the floor.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (sedating tertiary amine)

A sedating tertiary amine TCA with weak SERT and NET activity; the principal effect is dopaminergic and antihistaminergic.

Abstract

Trimipramine (3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine; CAS 739-71-9; molecular formula C20H26N2; molecular weight 294.43) is a 2-methylated dibenzazepine TCA approved by the FDA in 1979 under the trade name Surmontil. The methyl substitution at the propanamine’s beta carbon disrupts transporter binding: SERT Ki approximately 150 nM, NET Ki approximately 2400 nM, both several orders of magnitude weaker than amitriptyline or imipramine. The therapeutic effect is therefore primarily attributed to potent H1 (Ki approximately 0.27 nM, comparable to first-generation antihistamines), 5-HT2A, alpha-1, and D2 antagonism. The compound is among the most sedating TCAs in clinical use and is used preferentially in depression with severe insomnia. Plasma half-life is 16 to 40 hours; metabolism is via CYP2D6, CYP2C19, CYP3A4. Used as a reference compound for non-transporter TCA mechanism research; the H1 and dopaminergic profiles distinguish it from typical TCA pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-222Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Clomipramine

Plain-language summaryIntrigue 64 / 100

Clomipramine (Anafranil) is a tricyclic antidepressant with one chlorine atom added to imipramine, a small change that flips the selectivity sharply toward serotonin. It is in fact the most potent serotonin reuptake blocker in the entire tricyclic class, with affinity rivaling modern SSRIs. The active leftover after liver metabolism then shifts steady-state activity back toward norepinephrine, so the drug ends up doing both jobs over a 24-hour period. It is the only tricyclic with FDA approval for OCD and remains a third-line option for severe OCD when SSRIs fail. The usual tricyclic burdens (sedation, anticholinergic effects, cardiac risk in overdose) all apply. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

45/100

The gold-standard TCA for OCD research but a closed mechanistic frontier with deep evidence and low novelty

Look, clomipramine is one of those compounds where the resume is genuinely impressive but the research horizon has mostly closed. Developed at Geigy in the early 1960s and FDA-approved in 1989 specifically for OCD, it’s been the clinical anchor in treatment-resistant obsessive-compulsive disorder for over three decades. The SERT Ki of roughly 0.28 nM is remarkable for a TCA. Nothing else in the class touches it. And the parent/metabolite pharmacology has a quietly interesting wrinkle: clomipramine is SERT-dominant, but CYP3A4 and CYP2C19-driven demethylation produces N-desmethylclomipramine, a NET-preferring secondary amine, so at steady state you get dual monoaminergic coverage without deliberately engineering it. Thats a legitimately non-trivial pharmacokinetic story.

But none of that is new. The SERT mechanism was worked out decades ago. The OCD indication is mature to the point where the main clinical question is how it compares to SSRIs in treatment-resistant cases, and that question has been asked and partially answered many times over. The off-target burden, muscarinic block, H1 antagonism, alpha-1 and sodium channel activity, makes clomipramine a dirty probe for anything requiring clean SERT signal. If you need a SERT-selective tool in a model system, you’re reaching for citalopram or escitalopram, not this.

Where clomipramine still earns real bench value is as a reference standard in OCD neurobiology. The serotonin hypothesis of OCD is actually more complex than it sounds: there’s ongoing work around 5-HT2A contributions, orbitofrontal circuit modulation, and the genuinely unresolved question of why SERT saturation matters more in OCD than in other anxiety-adjacent disorders. Clomipramine is the clinical anchor for those comparisons. We also think the cataplexy research angle is underappreciated; it remains one of the few compounds with both mechanistic plausibility and real clinical signal in narcolepsy-associated cataplexy, and that’s a small but legitimate research context.

Honestly, the evidence quality here is as high as it gets. Decades of RCTs, multi-site replication, clear regulatory validation. But thats almost the problem: when evidence is this mature, the interesting questions are mostly downstream of the compound, not about it. What we don’t like about recommending this as a primary research focus is that a bench investigator picking it up today is almost certainly asking a comparative or clinical question, not a mechanism-frontier question. That makes it a solid reference tool and a useful historical benchmark. It’s not where serious research resources go to find new answers.

Novelty

20

Mechanism promise

25

In-category differentiation

45

Evidence quality

75

Translational signal

70

Research bench value

55

Rationale Clomipramine scores high on evidence quality and translational signal (FDA-approved, decades of replicated OCD RCTs, reference-standard status) but low novelty and mechanism scores drag the overall down hard; the SERT story is fully mature and the off-target burden makes it a poor clean probe for mechanism work despite its unique clinical niche.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (chlorinated tertiary amine)

A chloro-substituted TCA with the most potent SERT inhibition in the class; the only TCA with FDA approval for OCD.

Abstract

Clomipramine (3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; CAS 303-49-1; molecular formula C19H23ClN2; molecular weight 314.85) is a 3-chloro-substituted analog of imipramine developed at Geigy and approved by the FDA in 1989 under the trade name Anafranil. The chloro substitution shifts transporter selectivity sharply toward SERT (SERT Ki approximately 0.28 nM, the most potent in the TCA class; NET Ki approximately 38 nM). The active metabolite N-desmethylclomipramine (formed via CYP3A4/CYP2C19) is a NET-preferring secondary amine, producing balanced steady-state monoaminergic activity from a SERT-dominant parent. Off-target activity parallels other tertiary amine TCAs: muscarinic, H1, alpha-1, and sodium channel block. Plasma half-life is 19 to 37 hours. The compound is the only TCA with FDA approval for obsessive-compulsive disorder, an indication where the SSRI class typically requires higher doses; clomipramine remains a benchmark in treatment-resistant OCD. Used as the reference SERT-potent TCA in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-220Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Protriptyline

Plain-language summaryIntrigue 41 / 100

Protriptyline (Vivactil) is a secondary-amine tricyclic antidepressant from 1967 with one defining quirk: it is activating rather than sedating, which is the opposite of nearly every other drug in the class. The activating profile comes from preferential norepinephrine pump blockade combined with relatively little antihistamine activity. That made it historically useful for depressed patients with hypersomnia who needed alertness rather than further sedation. It has a long half-life because the liver metabolizes it slowly. Rarely prescribed now, displaced by SNRIs like duloxetine that achieve similar activation with much better tolerability. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

28/100

A 1967-approved TCA with a niche activating profile and almost no modern research frontier

Look, protriptyline is a real drug with a real effect. FDA approved in 1967, still prescribed, pharmacologically coherent. The case for it has always rested on a single differentiating fact: among the tricyclics, it doesn’t sedate. Most of the class leans heavily sedating via H1 blockade, but protriptyline’s relatively low H1 affinity and its NET-dominant profile (Ki around 1.4 nM at the norepinephrine transporter versus roughly 20 nM at SERT) tip the balance toward activation. That matters clinically, particularly in depression complicated by hypersomnia or narcolepsy-related mood disorder. The half-life situation is unusual too: 54 to 92 hours is long even by TCA standards, driven by sluggish CYP2D6 metabolism, which creates both a forgiving dosing window and a complicated clearance picture when coadministering.

Here’s the thing though: none of that is news. The pharmacology was described and characterized decades ago. The NET-over-SERT selectivity angle has been studied far more rigorously in compounds like reboxetine and atomoxetine, and the wakefulness-promoting space now belongs to orexin-pathway agents, modafinil, and the solriamfetol class. If you’re building a research program around activating antidepressant pharmacology, you’re not reaching for protriptyline as your probe. It’s burdened by the full TCA liability profile: muscarinic blockade, sodium channel effects, alpha-1 antagonism, narrow therapeutic index. These are not features that help you isolate a mechanism.

The evidence base is approved-drug-real, which means there’s clinical data going back to the 1960s. But TCA-era trials dont meet modern methodological standards. You’re looking at small, non-blinded, poorly-controlled studies by today’s metrics. Multi-decade literature exists, but a lot of it is descriptive case series or comparisons to other TCAs, not placebo-controlled designs with preregistered endpoints. The narcolepsy-depression comorbidity literature is genuinely thin and mostly observational.

We think the honest bench value here is narrow: if youre specifically studying secondary amine TCA pharmacokinetics, CYP2D6-driven extended half-life effects, or the NET-dominant TCA subclass as a historical reference point, protriptyline has a role. That’s a specific niche, not a broad research priority. For anything involving the activating-antidepressant mechanism today, the tools have moved on. Protriptyline remains useful the way a well-characterized historical reference standard is useful: occasionally, deliberately, and not as a centerpiece of a serious contemporary program.

Novelty

10

Mechanism promise

20

In-category differentiation

25

Evidence quality

45

Translational signal

48

Research bench value

28

Rationale Protriptyline scores low across novelty and differentiation because it is a mid-century TCA with no mechanism surprise and no serious modern competition driving renewed investigation; its higher NET selectivity is real but bupropion and modern SNRIs have absorbed that research territory entirely. Evidence quality and translational signal get modest credit for FDA approval and clear clinical effect, but neither dimension rescues the compound’s place in a contemporary research priority stack.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (secondary amine, activating)

A secondary amine TCA distinguished by activating rather than sedating subjective profile; useful in depression with hypersomnia.

Abstract

Protriptyline (N-methyl-3-(5H-dibenzo[a,d]cyclohepten-5-yl)propan-1-amine; CAS 438-60-8; molecular formula C19H21N; molecular weight 263.38) is a secondary amine TCA approved by the FDA in 1967 under the trade name Vivactil. Distinct among TCAs for an activating subjective profile that contrasts with the sedation typical of the class; the activating profile is attributed to relatively higher NET-to-SERT selectivity and reduced H1 antagonism. NET Ki approximately 1.4 nM, SERT Ki approximately 20 nM. Plasma half-life is exceptionally long (54 to 92 hours) owing to slow CYP2D6 metabolism. The activating profile makes protriptyline a niche choice for depression with prominent hypersomnia or fatigue, including narcolepsy-associated depression where the wakefulness-promoting effect is therapeutic. Off-target activity is otherwise typical of secondary amine TCAs: muscarinic, mild H1, alpha-1, and sodium channel block. Approved for major depressive disorder; rarely first-line today owing to TCA-class limitations. Used as a reference compound for activating TCA pharmacology and in narcolepsy-related comorbidity research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-221Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Imipramine

Plain-language summaryIntrigue 60 / 100

Imipramine is historically the most important antidepressant ever made: Roland Kuhn at Geigy noticed in 1958 that this antihistamine candidate unexpectedly lifted depressed patients’ moods, which kicked off the entire monoamine theory of depression and the modern era of psychiatric pharmacology. Mechanically it blocks the serotonin and norepinephrine pumps in roughly balanced fashion, while also blocking acetylcholine, histamine, and alpha-1 adrenergic receptors as side activities. Today it sees mostly historical and academic use, plus a niche role in nocturnal enuresis (bedwetting) in children. The cardiac sodium channel block makes overdose lethal, which is one reason SSRIs displaced it once they became available. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

34/100

The 1958 prototype TCA, historically foundational but superseded by cleaner tools at every research axis

Look, imipramine is the Adam compound of synthetic antidepressant pharmacology. Roland Kuhn’s 1958 Geigy observation that the dibenzazepine scaffold relieved depressive symptoms launched the monoamine hypothesis and gave the field its first real conceptual framework. That history is genuinely significant. What the rubric asks is something different: how compelling is THIS compound as an active bench target right now, and the honest answer is, not very.

The mechanism is completely characterized and has been for decades. SERT inhibition at roughly 1 nM Ki, NET inhibition at ~21 nM, plus a well-mapped off-target profile covering muscarinic M1, H1, alpha-1 adrenergic, and voltage-gated sodium channels. The off-target hits that were once clinical liabilities remain liabilities now, not research opportunities. Nobody’s building a new program around imipramine’s anticholinergic activity when you can isolate those mechanisms cleanly elsewhere with better-characterized probes.

The differentiation problem is the sharpest drag here. Imipramine is superseded by its own active metabolite: desipramine is a cleaner, more NET-selective secondary amine that most investigators reach for when they want a TCA probe for norepinephrine transporter work specifically. For SERT-selective work, the entire SSRI class exists. For balanced dual inhibition, duloxetine and venlafaxine offer better tolerability and considerably cleaner pharmacology. Imipramine loses on almost every axis to something developed after it. Thats not a knock on historical significance, its just the reality of a 67-year-old compound in a mature drug class where every successive generation improved on the scaffold.

Where it retains real value is narrow: positive control in pharmacology assays requiring the canonical first-generation TCA, CYP2D6 and CYP2C19 probe substrate work, and research programs specifically examining the TCA class for historical comparison or mechanistic archaeology. The evidence base is genuinely solid, sixty-plus years of replicated clinical data, FDA approval across MDD, enuresis, and panic disorder, robust translational signal. But that signal describes clinical applications modern practice has largely moved past, and solid old evidence doesn’t make a compound interesting.

We think the honest landing for imipramine is important reference compound with narrow active bench utility. The evidence quality and translational signal keep the score from falling further, but the novelty floor and severely penalized differentiation pull it squarely into the same tier as piracetam: historically central to the field, currently deprioritized by most investigators chasing something with more headroom.

Novelty

15

Mechanism promise

22

In-category differentiation

15

Evidence quality

65

Translational signal

65

Research bench value

45

Rationale Imipramine scores hard at the bottom of novelty and differentiation because it’s a 1958 compound outcompeted by its own active metabolite (desipramine) and the entire SSRI/SNRI class; evidence quality and translational signal are genuinely solid but for indications modern practice has largely moved past, producing an overall that sits in the same tier as piracetam.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (tertiary amine; first synthetic antidepressant)

The first synthetic antidepressant; the parent compound of the TCA class and the historical reference for monoamine theory of depression.

Abstract

Imipramine (3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; CAS 50-49-7; molecular formula C19H24N2; molecular weight 280.41) is a dibenzazepine tertiary amine TCA developed at Geigy by Roland Kuhn in 1958, the first synthetic compound demonstrated to relieve depressive symptoms in clinical trial. The historical observation underpinned the catecholamine hypothesis of depression and launched modern psychopharmacology. SERT and NET affinities are balanced (SERT Ki approximately 1 nM, NET Ki approximately 21 nM); the active metabolite desipramine is a NET-preferring secondary amine. Off-target activity parallels amitriptyline: muscarinic, H1, alpha-1, and sodium channel block. Plasma half-life is 11 to 25 hours; metabolism is via CYP2D6 and CYP2C19. Approved for major depressive disorder; clinical use today focuses on enuresis (bedwetting) in children (low-dose for anticholinergic and alpha-1 effects on bladder) and panic disorder. The TCA cardiotoxicity profile is the principal limitation. Used as the historical reference TCA and the prototype monoamine reuptake inhibitor in pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-218Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Desipramine

Plain-language summaryIntrigue 53 / 100

Desipramine (Norpramin) is the active leftover of imipramine, FDA-approved in 1964, and the most norepinephrine-selective tricyclic antidepressant ever brought to market. The shift in selectivity comes from removing one methyl group from imipramine. The strongly noradrenergic profile makes it one of the more activating tricyclics and useful in attention deficit research, although it never gained an ADHD label. Compared to its parent it has lower anticholinergic and antihistamine burden, so it is somewhat better tolerated, but it shares the cardiac conduction problems of the whole tricyclic class and overdose is dangerous. Used in treatment-resistant depression and some neuropathic pain protocols. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

44/100

The canonical NET-selective TCA; useful as a noradrenergic reference probe but essentially exhausted as a research frontier

Look, desipramine is about as established as it gets in the TCA class. FDA-approved in 1964, it’s been the reference standard for NET-selective tricyclic pharmacology for sixty years. That dual status, canonical probe on one hand and dated workhorse on the other, is exactly what drives the score here.

The NET selectivity is real and it matters. A Ki of roughly 0.83 nM at NET versus 17 nM at SERT gives you a selectivity ratio around 20-fold, which is genuinely useful if you’re trying to dissect noradrenergic from serotonergic contributions in a mixed-reuptake experiment. Compared to imipramine, the parent compound, desipramine sheds meaningful muscarinic (M1 Ki around 200 nM) and H1 load while keeping the NET hit clean. For any investigator running catecholamine reuptake assays, building pharmacological controls, or studying NE dynamics in pain or ADHD-relevant circuits, its position as the canonical NET-selective TCA is hard to displace within that specific context. Thats the bench case for having it in the library.

But thats also where the excitement ends. The mechanism, NET reuptake inhibition, has been understood for sixty years. The binding kinetics are fully characterized, the downstream noradrenergic effects are mapped, and the CYP2D6/CYP2E1 metabolism profile is textbook. What we dont like is that atomoxetine and reboxetine both exist now, offering higher NET selectivity without the TCA off-target load. For pure noradrenergic questions, those compounds have largely superseded desipramine except in historical comparisons or when the TCA scaffold itself is under study.

The evidence base is enormous. Multiple phase 3 trials, decades of replicated clinical data, strong meta-analytic signal for MDD. Translational signal is unambiguous in the sense that it works in people and that fact is exhaustively documented. But from a research novelty standpoint, a large evidence base on a 60-year-old compound means less remaining question to answer. There’s no frontier in the depression indication, the neuropathic pain angle is mature, and the ADHD off-label use lives in the shadow of better-characterized and more selective tools.

We think desipramine earns its place in the library as a reference compound and nothing more. Investigators comparing noradrenergic agents, running assay controls, or building pharmacological models of NE reuptake will want it on the shelf. For anything asking a genuinely new question about human biology, the novelty and mechanism scores drag the overall to where it belongs: a well-characterized, historically important, presently limited research tool.

Novelty

18

Mechanism promise

28

In-category differentiation

40

Evidence quality

72

Translational signal

68

Research bench value

60

Rationale Desipramine scores well on evidence and translational signal because its pharmacology is thoroughly characterized over six decades, but those same qualities crush its novelty and mechanism scores. Its bench value is real but narrow: it functions as a reference standard for NET-selective TCA comparisons, not as a frontier compound worth pursuing for new biology.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (secondary amine)

The N-desmethyl active metabolite of imipramine; the most NET-selective TCA in clinical use.

Abstract

Desipramine (3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine; CAS 50-47-5; molecular formula C18H22N2; molecular weight 266.38) is the N-desmethyl active metabolite of imipramine, approved by the FDA in 1964 under the trade name Norpramin. The compound is the most NET-selective TCA in clinical use (NET Ki approximately 0.83 nM, SERT Ki approximately 17 nM, ratio approximately 20). Off-target activity is reduced compared to imipramine: muscarinic (M1 Ki approximately 200 nM), H1 (Ki approximately 60 nM), and alpha-1 (Ki approximately 100 nM) antagonism are all weaker than the parent compound, producing a cleaner profile though still TCA-like. Plasma half-life is 15 to 24 hours; metabolism is via CYP2D6 and CYP2E1. Approved for major depressive disorder; used at higher doses (150 to 300 mg) for moderate-severe depression, at lower doses for ADHD (off-label) and neuropathic pain. Sodium channel block and consequent cardiotoxicity in overdose remain limitations. Used as the canonical NET-selective TCA in mechanism studies and as a reference compound for noradrenergic pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-219Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Nortriptyline

Plain-language summaryIntrigue 56 / 100

Nortriptyline (Pamelor, Aventyl) is the active leftover of amitriptyline, sold separately after FDA approval in 1964. The body strips one methyl group off amitriptyline to produce nortriptyline, and that small change shifts the drug toward blocking the norepinephrine pump preferentially with much less serotonin activity. It also drops the muscarinic and antihistamine load somewhat, which makes it more tolerable than the parent compound. Among older tricyclics it has the cleanest defined therapeutic blood-level window (50 to 150 ng/mL), which means clinicians can dose it precisely with a blood test rather than guessing. Used for depression, neuropathic pain, and migraine prevention. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

A well-characterized legacy TCA with real bench utility but minimal novelty and largely superseded clinical standing

Look, nortriptyline is what happens when pharmacology matures past a compound. Approved in 1964, it’s the N-desmethyl metabolite of amitriptyline, and that metabolic parentage is itself telling: the original compound was already considered a workhorse before nortriptyline entered independent clinical use. The mechanism is completely mapped. NET Ki around 4 nM, SERT closer to 18 nM, meaningful H1 antagonism, reduced but real muscarinic load. Every branch of that receptor profile has been studied to exhaustion across multiple decades in multiple labs. Thats not a criticism of the compound’s history; it just means a serious investigator isn’t going to find mechanistic surprises here.

Where nortriptyline does outperform amitriptyline is tolerability, specifically the lower anticholinergic burden (M1 Ki roughly 150 nM versus 18 nM for the parent), and that difference is real and clinically meaningful. But the comparison set matters. Against modern SNRIs like duloxetine for neuropathic pain, or against varenicline for smoking cessation, nortriptyline is second-line or lower across nearly every approved and off-label indication. It hasn’t defined its class; it refined a position within a class that’s mostly been vacated by newer chemotypes.

The evidence quality is actually one of the stronger aspects of the profile. Sixty years of clinical data, well-established therapeutic plasma monitoring windows (50 to 150 ng/mL), CYP2D6 metabolism characterized in detail, interaction profiles documented across hundreds of polypharmacy combinations. That depth of evidence is genuinely useful for some research designs and shouldn’t be dismissed. The translational signal is also real: nortriptyline works for depression, works for neuropathic pain, and the smoking cessation signal is well-replicated even if the effect size is modest against better alternatives.

What we think is most honest here: nortriptyline retains specific research value as the canonical secondary amine TCA reference compound. If you’re studying NET-preferring reuptake inhibition in a TCA scaffold, or comparing anticholinergic burden across tricyclic structures, it’s the right tool. That use case is narrow but legitimate, and it’s what keeps the bench_value score from bottoming out. But as an object of primary research interest, honestly, there isn’t much frontier left. The compound doesn’t unlock new biology, the indication space is saturated with better options, and the mechanism has no unexplored angles that the literature hasn’t already addressed multiple times. Score accordingly.

Novelty

18

Mechanism promise

22

In-category differentiation

28

Evidence quality

68

Translational signal

62

Research bench value

55

Rationale Nortriptyline scores low on novelty and mechanism because it is a 60-year-old TCA with a thoroughly mapped pharmacology; it earns back points on evidence quality and translational signal given decades of real clinical use, and modest bench_value credit as the canonical secondary amine TCA reference compound in mechanistic studies.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (secondary amine)

The N-desmethyl active metabolite of amitriptyline; a NET-preferring TCA with a more favorable side effect profile.

Abstract

Nortriptyline (3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methylpropan-1-amine; CAS 72-69-5; molecular formula C19H21N; molecular weight 263.38) is the N-desmethyl active metabolite of amitriptyline, marketed independently as Pamelor and Aventyl after FDA approval in 1964. As a secondary amine TCA, the compound exhibits substantially greater NET selectivity than amitriptyline (NET Ki approximately 4 nM, SERT Ki approximately 18 nM) and reduced muscarinic antagonism (M1 Ki approximately 150 nM versus 18 nM for amitriptyline), producing a cleaner side effect profile. H1 antagonism remains significant (Ki approximately 10 nM) and contributes to residual sedation, but the anticholinergic burden is meaningfully lower. Plasma half-life is 18 to 35 hours; metabolism is via CYP2D6 (primary). Approved for major depressive disorder; widely used at low dose (10 to 75 mg) for chronic pain, neuropathy, and as a smoking cessation aid (off-label). Therapeutic plasma concentrations are well-defined (50 to 150 ng/mL) and routinely monitored, distinguishing nortriptyline from most modern antidepressants. Used as the canonical secondary amine TCA in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-217Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Mianserin

Plain-language summaryIntrigue 47 / 100

Mianserin is the older European cousin of mirtazapine, developed at Organon in the 1960s and marketed across Europe and Asia from 1976 onward. It was never approved in the United States. Like mirtazapine it boosts norepinephrine and serotonin output by blocking the auto-brake on those neurons rather than blocking the reuptake pumps. The differences are subtle: mianserin has a wider spread of off-target receptor activity and a small but historically significant risk of bone marrow suppression, which is part of why mirtazapine ultimately replaced it in most markets. Mianserin remains useful as a research tool for understanding the alpha-2 adrenergic receptor mechanism. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

Superseded tetracyclic antidepressant with limited modern research appeal beyond mirtazapine comparison work

Look, mianserin is the compound mirtazapine quietly replaced. Organon developed it in the 1960s, got it onto the European and Asian market in 1976, and then spent the next two decades iterating toward a safer, cleaner successor. That successor is mirtazapine. The story of mianserin is, in a meaningful sense, the story of what had to be fixed to get there.

The mechanism is genuinely interesting in outline: alpha-2 adrenergic auto- and heteroreceptor antagonism drives monoaminergic disinhibition in a way thats actually pharmacologically elegant compared to older tricyclics. You also get 5-HT2A, 5-HT2C, H1, and alpha-1 antagonism in the mix. But every one of those receptor interactions is better characterized in mirtazapine, and mirtazapine does it without the agranulocytosis and aplastic anemia risk that haunted mianserin’s clinical career — estimated at roughly 1 in 1500 to 1 in 5000 cases, which is hard to ignore when a structurally similar compound with a cleaner safety profile exists.

The evidence base is real. Decades of European clinical use, multiple controlled trials, established PK (half-life 21-61 hours, CYP2D6 metabolism, active demethyl-mianserin metabolite). This isnt a compound with thin preclinical-only data. But the evidence is aging, the trials are mostly pre-2000, and virtually no active research programs are centering mianserin as a primary object of study. The literature is large because it was used, not because researchers are still reaching for it.

What bench value mianserin retains is narrow. It works as a reference compound in alpha-2 pharmacology comparisons and as a historical control when studying tetracyclic antidepressant mechanisms. If your research question specifically involves comparing first- versus second-generation tetracyclics, or quantifying the receptor-selectivity improvements that mirtazapine achieved, then mianserin is the natural comparator. Outside that framing, its hard to construct a reason to run an experiment with mianserin when mirtazapine exists and is more widely available.

We dont think this belongs on a frontier research shortlist. The novelty is low, the differentiation is negative relative to its own successor, and the research signal it carries is historical rather than prospective. Serious investigators working in adrenergic or tetracyclic antidepressant pharmacology probably already know where mianserin fits. For anyone else, the compound earns a file entry and not much more.

Novelty

18

Mechanism promise

28

In-category differentiation

18

Evidence quality

58

Translational signal

55

Research bench value

30

Rationale Mianserin’s core mechanism is well-understood and has been materially improved upon by mirtazapine, which retains the pharmacologically interesting alpha-2 antagonism while shedding the agranulocytosis liability; novelty and differentiation scores drag the overall down hard. Evidence quality and translational signal are real but historically bounded and largely irrelevant to active research programs.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tetracyclic alpha-2 adrenergic antagonist

A first-generation tetracyclic antidepressant; the structural and mechanistic precursor to mirtazapine.

Abstract

Mianserin (1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine; CAS 24219-97-4; molecular formula C18H20N2; molecular weight 264.37) is a tetracyclic antidepressant developed at Organon in the 1960s and marketed in Europe and Asia from 1976 (never FDA approved for the US market). The compound is the structural and mechanistic precursor to mirtazapine, sharing the alpha-2 adrenergic auto/heteroreceptor antagonism that increases monoaminergic release. Mianserin additionally exhibits 5-HT2A, 5-HT2C, H1, and alpha-1 antagonism but with a less favorable receptor selectivity profile than mirtazapine. Notable for a higher incidence of agranulocytosis and aplastic anemia than mirtazapine (estimated 1 in 1500 to 1 in 5000 cases) which contributed to its replacement in clinical practice. Plasma half-life is 21 to 61 hours; metabolism is via CYP2D6 with active demethyl-mianserin metabolite. Used as a reference tetracyclic and alpha-2 antagonist in mechanism studies; less common in clinical use today owing to mirtazapine availability.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-214Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 42 43 44 45 46 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.